Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07652203 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Impact of Propranolol on the Prognosis of Patients With Decompensated Cirrhosis and MELD Score > 9

StatusNot Yet Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Jun 2026 to Sep 2026 Show 4 more changesShow less
    • Eligibility criteria expanded, about 15 words
    • Secondary endpoints: details revised at 2 of 5 entries
    • Study description revised
    • Publications: details revised at 5 of 5 entries
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Non selective beta blockers (NSBBs), such as propranolol and nadolol, are mainstay therapies for portal hypertension in cirrhosis, but their efficacy and safety vary depending on the stage of the disease. Emerging evidence suggests that NSBBs may worsen the prognosis of advanced cirrhosis, especially in patients with a model for end-stage liver disease (MELD) score of \>9. The purpose of this randomized controlled trial is to evaluate the effects of the use of propranolol as recommended by the guideline on the prognosis in cirrhotic patients with a MELD score of \>9.
Trial Details
NCT Number NCT07652203
Lead Sponsor General Hospital of Shenyang Military Region
Conditions
(from sponsor)		 Cirrhosis
Related terms Fibrosis
Enrollment 466 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov